Ppi-1019
Grundinformationen
- CAS
290828-45-4- Standard-SMILES
CN[C@H](CC(C)C)C(=O)N[C@@H](C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@H](CC(C)C)C(N)=O)C(C)C- InChIKey
TUSUWHFYKZZRIG-JQWMYKLHSA-N- Summenformel
- C36H54N6O5
- Durchschnittliche Molmasse
- 650,9 g/mol
- Monoisotopische Masse
- 650,41556884
Überblick
Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
Namen und Bezeichner
- Bevorzugter Name
- Ppi-1019
- IUPAC
- (2R)-4-methyl-2-[[(2R)-2-[[(2R)-2-[[(2R)-3-methyl-2-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]butanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]pentanamide
- Englischer Name
- N-Methyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-D-LeucinaMide
- Summenformel
- C36H54N6O5
- Molmasse
- 650.85116
Namen und Synonyme
PPI-1019290828-45-4PPI 1019UNII-2F25P9Y22O2F25P9Y22O(2R)-4-METHYL-2-(((2R)-2-(((2R)-2-(((2R)-3-METHYL-2-(((2R)-4-METHYL-2-(METHYLAMINO)PENTANOYL)AMINO)BUTANOYL)AMINO)-3-PHENYL-PROPANOYL)AMINO)-3-PHENYL-PROPANOYL)AMINO)PENTANAMIDE(2R)-N-((1R)-1-(((1R)-1-(((1R)-1-(((1R)-1-carbamoyl-3-methylbutyl)carbamoyl)-2-phenylethyl)carbamoyl)-2-phenylethyl)carbamoyl)-2-methylpropyl)-4-methyl-2-(methylamino)pentanamide(2R)-N-[(1R)-1-{[(1R)-1-{[(1R)-1-{[(1R)-1-carbamoyl-3-methylbutyl]carbamoyl}-2-phenylethyl]carbamoyl}-2-phenylethyl]carbamoyl}-2-methylpropyl]-4-methyl-2-(methylamino)pentanamideRefChem:175671APAND-Leucinamide, N-methyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-(2R)-4-Methyl-2-[[(2R)-2-[[(2R)-2-[[(2R)-3-methyl-2-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]butanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]pentanamide
Weitere Namen anzeigen
PPI1019N-Methyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-D-LeucinaMide
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 3,2
- Polarare Oberfläche (TPSA)
- 172 Ų
- H-Brücken-Donoren
- 6
- H-Brücken-Akzeptoren
- 6
- Frei drehbare Bindungen
- 19
- Schwere Atome
- 47
- Formalladung
- 0
- Komplexität
- 1.010
Experimentelle und physikochemische Eigenschaften
DrugsPharmaceuticals -> Listed in ZINC15
Chemie und Industrie
Pharmakologische Informationen
Mechanism of Action
PPI-1019 (Apan) inhibits the aggregation of beta-amyloid and its associated nerve cell toxicity. In addition, Apan reaches the brain in quantities that are sufficient to block the aggregation of beta-amyloid molecules and alter the course of the disease. Accumulation of beta-amyloid in the brain is often thought of as a defect in the ability to clear beta-amyloid from the brain through the cerebral spinal fluid (CSF). Both humans and transgenic mice with Alzheimer's disease plaques show increased levels of beta-amyloid in the brain and decreased levels in the CSF. Transgenic mice treated with Apan show significant increases in beta-amyloid levels in the CSF, indicating that Apan is able to mobilize beta-amyloid in the brain and may be facilitating its clearance.
Anbieter6 Anbieter
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
江西辐氨生物技术有限公司15002819872 · [email protected]
上海一飞生物科技有限公司021-65675885 18964387627 · [email protected]
TargetMol中国（陶术生物）15002134094 · [email protected]
上海阿摩尔生物科技有限公司13370042665 18916960931 · [email protected]
AFINE CHEMICALS LIMITED+86-571-85134551 +86-18958018566 · [email protected]
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…